Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Omni Voluntarily Modifies Inholtra Ads Following NAD Review

This article was originally published in The Tan Sheet

Executive Summary

Future ads for Omni Nutraceuticals' Inholtra Natural Pain Formula combination supplement will limit content comparisons to other glucosamine-containing products, the company agrees in NAD's recently released June Case Reports.

You may also be interested in...

Omni Nutraceuticals

Inholtra Joint Pain analgesics with glucosamine and chondroitin are monograph compliant despite FDA concerns about OTC/supplement combination products, Omni says. A launch date has not been set for the line of four analgesics (aspirin, acetaminophen, ibuprofen and naproxen sodium ) and the company is still in talks with FDA regarding labeling. Omni says the products differ from other combinations because they will be labeled only with OTC indications, claims and dosing schedules approved under existing monographs, not structure/function claims. FDA recently sent letters discouraging several companies from marketing products with both OTC and supplement claims, and promised future guidance on the issue (1"The Tan Sheet" June 12, p. 3). Omni will list glucosamine and chondroitin as "inactive ingredients" on labeling but will prominently display them on packaging, relying on consumers' knowledge of the ingredients

Glucosamine sulfate and osteoarthritis

Supplement ingredient may reduce the signs and symptoms of osteoarthritis of the knee, Jean-Yves Reginster, MD/PhD, et al., University of Liege, report at the American College of Rheumatology's annual scientific meeting in Boston Nov. 15. The double-blind, randomized, three-year trial compared 106 patients taking 1,500 mg glucosamine sulfate daily with 106 subjects taking placebo. Those taking the supplement showed no change in joint space narrowing, which was measured by radiograph, while the space between joints in those taking placebo narrowed an average of .08 mm to .1 mm per year. The researchers called on further studies to confirm the results; NCCAM recently announced it was funding a multicenter study on glucosamine and knee OA ("The Tan Sheet" Sept. 20, p. 10)

Inholtra Line Extensions, Price Roll Back Promoted In $2 Mil. Ad Campaign

Irwin Naturals/4Health is extending its Inholtra natural joint pain relief formula franchise with two new dietary supplements - InholtraNow topical cream and Inholtra SulfaMax MSM formula. The products will begin shipping to health food and mass market outlets in mid-August.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts